MedTrace Logo

Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia

NCT05611593 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-03-07

No results posted yet for this study

Summary

The CSP-001-FOL1 clinical study is aimed to investigate whether local topical administration of FOL100 lotion will be safe for the patient and will not cause local or systemic skin or other adverse events. It is also aimed at indicating effectiveness as compared with oral Finasteride 1mg. In this non-blinded study, each patient will choose his preferred arm (oral finasteride or FOL100 location). During the study, safety and efficacy will be measured as well as usability.

Conditions

  • Androgenic Alopecia

Interventions

DRUG

FOL100

FOL100 lotion

DRUG

Propecia 1Mg Tablet

Oral Finasteride

Sponsors & Collaborators

  • Follicle Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Solli Brawer · Follicle Pharma Ltd

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-20
Primary Completion
2024-12-31
Completion
2025-02-28

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05611593 on ClinicalTrials.gov